 |
1 Disease |  |
67 Trials |
|
67 Trials |  |
1555 News |  |
| «12...1516171819202122232425...3940» |
- || pegenzileukin (SAR444245) / Sanofi
Trial completion date, Trial primary completion date: A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) (clinicaltrials.gov) - Aug 26, 2022
P1/2, N=80, Recruiting, Sponsor: Sanofi
Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2025 --> Jun 2026
- Libtayo (cemiplimab) / Regeneron
Second Line Cemiplimab for Locally Advanced Basal-Cell Carcinoma - A Real World Multi Center Experience (Golden Plenary) - Aug 25, 2022 - Abstract #EADV2022EADV_3260;
- | Trial completion date, Trial primary completion date, Checkpoint inhibition: Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy (clinicaltrials.gov) - Aug 23, 2022
P1, N=16, Recruiting, Sponsor: University of Southern California
Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2025 --> Jun 2026 Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2023
- || Libtayo (cemiplimab) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker: Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges. (Pubmed Central) - Aug 22, 2022
Despite the high tolerability and efficiency, the existence of some challenges has been revealed such as, resistance to immunotherapy, less availability of the biomarkers, and difficulty in appropriate patient selection. This review aims to accumulate evidence regarding the genetic alterations related to SCC, the factors that contribute to the potential benefits of immunotherapy, and the challenges to follow this treatment regime.
- || Odomzo (sonidegib) / Sun Pharma, Libtayo (cemiplimab) / Regeneron, Erivedge (vismodegib) / Roche
Review, Journal: Systemic Targeted Treatments for Basal Cell Carcinoma. (Pubmed Central) - Aug 22, 2022
The sonic hedgehog (SHH) inhibitors vismodegib and sonidegib are the only 2 first-line systemic medications approved for the treatment of locally aggressive basal cell carcinoma (BCC)...Cemiplimab, an immune checkpoint inhibitor (ICI), is now an approved second-line therapy for locally advanced or metastatic BCC...Given the high rate of recurrence and emerging concern regarding drug resistance, maintenance dosing regimens and potential synergism with other treatment modalities, such as radiotherapy or antifungal therapy, should be further explored. The use of SHH inhibitors in the neoadjuvant setting also is warranted, as it may allow for surgical management of previously inoperable cases of BCC.
- | Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap, UV1 / Zelluna
Enrollment open, Trial initiation date: LUNGVAC: Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 18, 2022
P2, N=138, Recruiting, Sponsor: Vestre Viken Hospital Trust
The use of SHH inhibitors in the neoadjuvant setting also is warranted, as it may allow for surgical management of previously inoperable cases of BCC. Not yet recruiting --> Recruiting | Initiation date: May 2022 --> Aug 2022
- || Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, IO biomarker: SiCARIO: Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer (clinicaltrials.gov) - Aug 15, 2022
P1/2, N=25, Not yet recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
- || Odomzo (sonidegib) / Sun Pharma, Libtayo (cemiplimab) / Regeneron, Erivedge (vismodegib) / Roche
Review, Journal: Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma. (Pubmed Central) - Aug 14, 2022
Small and low-risk BCCs, broad field cancerization, locally-advanced disease, metastatic disease, cosmetic concerns, or morbidity with surgical approaches raise consideration of other treatment modalities. We review herein a range of treatment approaches and advances in treatments for BCC, including standard excision, MMS, electrodesiccation and curettage, ablative laser treatment, radiation therapy, targeted molecular therapies, topical therapies, field therapies, immunotherapy, and experimental therapies.
- || SAR441000 / Sanofi, BioNTech
Enrollment change, Monotherapy: A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 12, 2022
P1, N=77, Active, not recruiting, Sponsor: Sanofi
We review herein a range of treatment approaches and advances in treatments for BCC, including standard excision, MMS, electrodesiccation and curettage, ablative laser treatment, radiation therapy, targeted molecular therapies, topical therapies, field therapies, immunotherapy, and experimental therapies. N=231 --> 77
- Libtayo (cemiplimab) / Regeneron
Cemiplimab for multiple advanced cutaneous squamous cell carcinoma in a 15-year-old male patient with Xeroderma Pigmentosum. (e-Poster Hall) - Aug 11, 2022 - Abstract #EADV2022EADV_1913;
- Libtayo (cemiplimab) / Regeneron
Realworld data of cemiplimab in advanced cutaneous squamous cell carcinoma in patients older than 85 inSpain (e-Poster Hall) - Aug 11, 2022 - Abstract #EADV2022EADV_1821;
- || Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: CEMI-LUNG: An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (clinicaltrials.gov) - Aug 9, 2022
P=N/A, N=300, Not yet recruiting, Sponsor: Sanofi
N=231 --> 77 Trial completion date: Jun 2028 --> Sep 2028 | Trial primary completion date: Jun 2028 --> Sep 2028
- |||||| Libtayo (cemiplimab-rwlc) / Regeneron
New trial, HEOR, Real-world evidence: REACT-CEMI: Real World Study on the Use of Cemiplimab in Adult Patients in UK (clinicaltrials.gov) - Aug 9, 2022
P=N/A, N=100, Active, not recruiting, Sponsor: Sanofi
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab (clinicaltrials.gov) - Aug 8, 2022
P1, N=44, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Jun 2028 --> Sep 2028 | Trial primary completion date: Jun 2028 --> Sep 2028 Trial completion date: Feb 2026 --> May 2026 | Trial primary completion date: Feb 2026 --> May 2026
- || Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Immune checkpoint blockades in gynecological cancers: A review of clinical trials. (Pubmed Central) - Aug 7, 2022
As revealed in phase III trials, pembrolizumab (a PD-1 antibody) improved the overall survival and progression-free survival in endometrial cancer patients with mismatch repair deficiency and cervical cancer patients with expressions of PD-L1...Other PD-1 antibodies, including dostarlimab and cemiplimab, also showed antitumor efficacy in clinical trials...Three completed phase III trials investigated anti-PD-L1 agents (atezolizumab and avelumab) in the treatment of ovarian cancer...Other strategies of ICB therapy which had showed potential clinical benefit in the treatment of gynecological cancers in early-phase trials need to be further evaluated in late-stage trials. The antitumor efficacy of ICB therapy is promising, and the key to making further progress in the treatment of gynecological cancers is to identify more biomarkers and explore innovative combination treatments with other targeted therapies.
- || Pexa-Vec (pexastimogene devacirepvec) / SillaJen
Enrollment closed: JX594-REN026: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma (clinicaltrials.gov) - Aug 5, 2022
P1b/2a, N=89, Active, not recruiting, Sponsor: SillaJen, Inc.
The antitumor efficacy of ICB therapy is promising, and the key to making further progress in the treatment of gynecological cancers is to identify more biomarkers and explore innovative combination treatments with other targeted therapies. Recruiting --> Active, not recruiting
- ||| Libtayo (cemiplimab) / Regeneron
During a live virtual event, Martin F. Dietrich, MD, PhD, discussed the results of the EMPOWER-Lung 1 and EMPOWER-Lung 3 trials of cemiplimab for non–small cell lung cancer. This is the second of 2 articles based on this event. #lcsm @DoctorDietrich https://t.co/pEMHEe1mCn (Twitter) - Aug 4, 2022
- | Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Aug 4, 2022
P2, N=0, Withdrawn, Sponsor: University of Miami
Recruiting --> Active, not recruiting N=44 --> 0 | Trial completion date: Sep 2025 --> Jul 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2025 --> Jul 2022
- ||| REGN5678 / Regeneron, Libtayo (cemiplimab) / Regeneron
REGN5678 Plus Cemiplimab Demonstrates Early Activity in mCRPC @drmnstein @ColumbiaPS #pcsm https://t.co/VKYybw05zX (Twitter) - Aug 3, 2022
- |||| Libtayo (cemiplimab) / Regeneron, Vesicare (solifenacin) / Astellas
$REGN onco pipeline relying on cemiplimab / Libtayo backbone expected catalyst (incl. 3 ESMO prez, of which 2 that I had spotted yesterdya in my #ESMO22 thread) CD20 & BCMA x CD3 #bispec #TCE recap (Twitter) - Aug 3, 2022
- Libtayo (cemiplimab) / Regeneron
C-POST Protocol Update: A Phase 3, Randomized, Double‑Blind Study of Adjuvant Cemiplimab vs. Placebo Post Surgery and Radiation Therapy in Patients with High‑Risk Cutaneous Squamous Cell Carcinoma (Henry B. Gonzalez Convention Center, Exhibit Hall 1) - Aug 1, 2022 - Abstract #ASTRO2022ASTRO_1418;
P3
N=44 --> 0 | Trial completion date: Sep 2025 --> Jul 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2025 --> Jul 2022 Not applicable (trial in progress)
- |||| Libtayo (cemiplimab) / Regeneron
Honored to present updates on non-#melanoma #skin #cancer including the @RambamHCC data on Cemiplimab #NMSC @sanofi (Twitter) - Jul 29, 2022
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: The Contributions of Cancer-Testis and Developmental Genes to the Pathogenesis of Keratinocyte Carcinomas. (Pubmed Central) - Jul 29, 2022
CTAs and developmental genes are emerging as important players in the pathogenesis of BCC and cSCC, positioning themselves as attractive candidate biomarkers and therapeutic targets requiring rigorous testing. Herein, we review the current research and offer perspectives on the contributions of CTAs and developmental genes to the pathogenesis of keratinocyte carcinomas.
- Libtayo (cemiplimab) / Regeneron
A phase II, multicenter, open-label, dose-finding study evaluating THIO sequenced with cemiplimab in patients with advanced NSCLC (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_3237;
P2
Adverse events will be evaluated according to NCI CTCAE v5.0. The trial is enrolling patients at sites in Europe and Australia.
- Libtayo (cemiplimab) / Regeneron
Phase II confirmatory study of cemiplimab (350mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6 (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2963;
P1, P2, P3
The most common grade ≥3 TEAEs were hypertension and pneumonia (each 3.6%), and general physical health deterioration (3.0%). Conclusions The group 6 primary analysis demonstrates a safety and efficacy profile that is consistent with that of the earlier groups of the study.
- Libtayo (cemiplimab) / Regeneron
Longer follow up of a real-world study of cemiplimab in advanced cutaneous squamous cell carcinoma: Focus on late toxicities and long term benefit (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2956;
However, some trAEs may occur even after several months from the start of treatment. Complete response is often maintained for long time.
- Libtayo (cemiplimab) / Regeneron
Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 3 subgroup analysis (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2524;
P3
Conclusions In pts with laNSCLC, 1L cemiplimab + chemo provided significant improvement in PFS, numerically longer OS, higher ORR, and longer durable response than control. The safety profile was consistent with that reported in the overall population of this study.
- Libtayo (cemiplimab) / Regeneron
Clinical interchangeability of programmed cell death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays for the treatment of first-line (1L) non-small cell lung cancer (NSCLC) with cemiplimab (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2507;
P3
SP263 is not approved and is under FDA review. Conclusions Similar efficacy was observed with the 22C3+ and SP263+ populations, demonstrating potential interchangeability of these PD-L1 IHC assays for selecting pts for treatment with 1L cemiplimab monotherapy for advanced NSCLC.
- Libtayo (cemiplimab) / Regeneron
CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2402;
P=N/A, P1,
In total, 95 (48.2%) pts discontinued treatment. Conclusions At this timepoint, the safety, tolerability, and effectiveness of cemiplimab in this real-world study of pts with advanced CSCC were consistent with results observed in the registration clinical trial (NCT02383212, NCT02760498).
- Libtayo (cemiplimab) / Regeneron
Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3 (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2393;
P2
There were no new safety signals identified on longer follow-up. Cemiplimab remains a standard of care option for advanced CSCC.
- BNT116 / BioNTech
LuCa-MERIT-1: First-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2345;
P1
Secondary endpoints are related to clinical activity, i.e., tumor assessments, as per RECIST 1.1. The first patient is planned to be dosed in May 2022, with enrolment expected for approximately 12 months.
- Libtayo (cemiplimab) / Regeneron
Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2281;
P3
Conclusions In aNSCLC with PD-L1 ≥50%, cemiplimab resulted in significant benefits over chemotherapy in overall change from baseline and delayed TTDD across multiple cancer-related and lung cancer-specific PROs across both histology subgroups. PRO results further support the favourable benefit-risk profile of cemiplimab across both subgroups.
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial primary completion date, Tumor mutational burden: NEO-CESQ: Neoadjuvant Plus Adjuvant Treatment with Cemiplimab in Cutaneaous Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 28, 2022
P2, N=25, Recruiting, Sponsor: Fondazione Melanoma Onlus
PRO results further support the favourable benefit-risk profile of cemiplimab across both subgroups. Trial primary completion date: Jun 2022 --> Oct 2022
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: NCI-2018-01313: Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery (clinicaltrials.gov) - Jul 28, 2022
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2022 --> Oct 2022 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- ||| SAR444200 / Sanofi
Enrollment open, Metastases: Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jul 28, 2022
P1/2, N=106, Recruiting, Sponsor: Sanofi
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Not yet recruiting --> Recruiting
- || Libtayo (cemiplimab-rwlc) / Regeneron, Erbitux (cetuximab) / Eli Lilly
Enrollment open: A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer (clinicaltrials.gov) - Jul 28, 2022
P1, N=10, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- || Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change, Trial completion date, Trial primary completion date: Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma (clinicaltrials.gov) - Jul 27, 2022
P1, N=61, Recruiting, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Recruiting N=41 --> 61 | Trial completion date: Sep 2023 --> Jan 2024 | Trial primary completion date: Sep 2023 --> Jan 2024
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) - Jul 26, 2022
P1, N=12, Recruiting, Sponsor: Dana-Farber Cancer Institute
N=41 --> 61 | Trial completion date: Sep 2023 --> Jan 2024 | Trial primary completion date: Sep 2023 --> Jan 2024 Trial completion date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jul 2022 --> Jan 2023
- Libtayo (cemiplimab) / Regeneron, fianlimab (REGN3767) / Regeneron, Sanofi
Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel) (7.2.F - Fécamp Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1690;
P1, P3
Conclusions Fianlimab + cemiplimab in advanced mel pts had a similar safety profile to anti–PD-1 agents; clinical activity in anti-PD-(L)1-naïve patients appears higher than previously reported for anti-PD-1 monotherapy or anti–LAG-3 + anti–PD-1. A phase 3 trial (NCT05352672) investigating fianlimab + cemiplimab in advanced mel pts is ongoing.
- Libtayo (cemiplimab) / Regeneron
Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis (7.2.E - Évry Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1577;
P3
Table: 519MO *Analysis of OS in the AC population and PD-L1 population subsets were exploratory with no adjustments for multiplicity. Conclusions With long-term follow-up, cemiplimab continues to show, in the overall population, a statistically significant and clinically meaningful improvement in OS vs chemo in pts with R/M cervical cancer after 1L platinum-based chemo.
- Libtayo (cemiplimab) / Regeneron
Neoadjuvant cemiplimab in patients (pts) with stage II–IV (M0) cutaneous squamous cell carcinoma (CSCC): Primary analysis of a phase II study (7.1.C - Cannes Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1461;
P2
The safety profile of neoadjuvant cemiplimab is consistent with previous anti-PD-1 monotherapy experience. Ongoing follow-up will describe disease-free survival.
- Libtayo (cemiplimab) / Regeneron
Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial (4.A - Antibes Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1422;
P3
Continued CEMI + chemo as 2L therapy provided meaningful and durable ORR and OS benefits and these results compare favorably to historical data of pts receiving chemo alone as 2L therapy (after immune-checkpoint inhibitor monotherapy). This data is the first report from a Phase 3 study providing therapeutic advantage to pts who progress after 1L PD1 monotherapy.
- || BNT112 / BioNTech
Enrollment closed, Monotherapy: PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (clinicaltrials.gov) - Jul 21, 2022
P1/2, N=115, Active, not recruiting, Sponsor: BioNTech SE
This data is the first report from a Phase 3 study providing therapeutic advantage to pts who progress after 1L PD1 monotherapy. Recruiting --> Active, not recruiting
- || Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial primary completion date: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (clinicaltrials.gov) - Jul 20, 2022
P1/2, N=109, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
- Libtayo (cemiplimab) / Regeneron
Cemiplimab-associated bullous pemphigoid--a rare cutaneous adverse reaction of PD1 inhibitors (glass aisle) - Jul 18, 2022 - Abstract #ADO2022ADO_562;
- Libtayo (cemiplimab) / Regeneron
Case report from the Oldenburg Skin Cancer Center: successful treatment of an inoperable squamous cell carcinoma with cemiplimab (glass aisle) - Jul 18, 2022 - Abstract #ADO2022ADO_368;
- Libtayo (cemiplimab) / Regeneron
Partial response to cemiplimab in a bilateral orbital infiltrating basal cell carcinoma of the midface (glass aisle) - Jul 18, 2022 - Abstract #ADO2022ADO_338;
- Libtayo (cemiplimab) / Regeneron
CemiSkin - First interim analysis of an observational study in patients with advanced squamous cell carcinoma of the skin (CSCC) treated with cemiplimab or other therapies (glass aisle) - Jul 18, 2022 - Abstract #ADO2022ADO_337;
- Libtayo (cemiplimab) / Regeneron
Pseudoprogression of a metastatic squamous cell carcinoma under cemiplimab with subsequent complete remission, but new cutaneous second tumors (glass aisle) - Jul 18, 2022 - Abstract #ADO2022ADO_332;
- Libtayo (cemiplimab) / Regeneron
Cemiplimab as a neoadjuvant therapeutic approach for advanced cutaneous squamous cell carcinoma (glass aisle) - Jul 18, 2022 - Abstract #ADO2022ADO_330;